SomaKit TOC 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0027 
Minor change in labelling or package leaflet not 
28/09/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10552
Periodic Safety Update EU Single assessment - 
06/07/2023 
n/a 
PRAC Recommendation - maintenance 
/202212 
edotreotide 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
IB/0024 
C.I.11.z - Introduction of, or change(s) to, the 
21/02/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0025 
A.1 - Administrative change - Change in the name 
13/02/2023 
and/or address of the MAH 
SmPC, 
Labelling and 
PL 
PSUSA/10552
Periodic Safety Update EU Single assessment - 
21/07/2022 
19/09/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202112 
edotreotide 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10552/202112. 
N/0023 
Minor change in labelling or package leaflet not 
04/05/2022 
19/09/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
R/0019 
Renewal of the marketing authorisation. 
16/09/2021 
12/11/2021 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
SomaKit TOC in the approved indication remains favourable 
and therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
PSUSA/10552
Periodic Safety Update EU Single assessment - 
22/07/2021 
16/09/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202012 
edotreotide 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10552/202012. 
IB/0020 
C.I.z - Changes (Safety/Efficacy) of Human and 
09/06/2021 
16/09/2021 
SmPC 
Veterinary Medicinal Products - Other variation 
IB/0021 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
06/05/2021 
16/09/2021 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0017/G 
This was an application for a group of variations. 
10/12/2020 
16/09/2021 
Annex II and 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PL 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
II/0015 
Update of sections 4.4, 4.5 and 4.6 of the SmPC in 
03/09/2020 
16/09/2021 
SmPC and PL 
Close contact with infants and pregnant women should be 
order to amend an existing warning extending the 
period during which close contact with infants and 
pregnant women should be restricted, add 
information on interactions with glucocorticosteroids 
and extend the period during which breastfeeding 
should be interrupted. The Package Leaflet is 
updated accordingly. Additionally, the MAH took the 
opportunity to update the details of local 
representatives. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IA/0016/G 
This was an application for a group of variations. 
28/08/2020 
n/a 
restricted during the first 12 hours after administration. 
Breastfeeding should be interrupted for 12 hours and the 
expressed feeds discarded. 
Repeated administration of high-doses of 
glucocorticosteroids prior to gallium (68Ga) edotreotide 
administration may cause insufficient SSTR2 expression for 
adequate visualization of somatostatin receptor-positive 
NETs. 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
PSUSA/10552
Periodic Safety Update EU Single assessment - 
09/07/2020 
n/a 
PRAC Recommendation - maintenance 
/201912 
edotreotide 
PSUSA/10552
Periodic Safety Update EU Single assessment - 
30/01/2020 
27/03/2020 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201906 
edotreotide 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10552/201906. 
II/0011 
B.II.e.1.a.3 - Change in immediate packaging of the 
12/12/2019 
27/03/2020 
SmPC 
finished product - Qualitative and quantitative 
composition - Sterile medicinal products and 
biological/immunological medicinal products 
IA/0013 
B.II.e.6.b - Change in any part of the (primary) 
15/10/2019 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
PSUSA/10552
Periodic Safety Update EU Single assessment - 
11/07/2019 
n/a 
PRAC Recommendation - maintenance 
/201812 
edotreotide 
IB/0008/G 
This was an application for a group of variations. 
21/01/2019 
n/a 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
PSUSA/10552
Periodic Safety Update EU Single assessment - 
17/01/2019 
n/a 
PRAC Recommendation - maintenance 
/201806 
edotreotide 
N/0009 
Minor change in labelling or package leaflet not 
17/12/2018 
01/10/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0006 
B.II.b.3.z - Change in the manufacturing process of 
01/10/2018 
01/10/2019 
SmPC 
the finished or intermediate product - Other variation 
PSUSA/10552
Periodic Safety Update EU Single assessment - 
12/07/2018 
n/a 
PRAC Recommendation - maintenance 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
/201712 
edotreotide 
PSUSA/10552
Periodic Safety Update EU Single assessment - 
11/01/2018 
n/a 
PRAC Recommendation - maintenance 
/201706 
edotreotide 
IB/0003 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
12/06/2017 
07/06/2018 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
N/0002 
Minor change in labelling or package leaflet not 
08/05/2017 
07/06/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0001 
Minor change in labelling or package leaflet not 
05/04/2017 
07/06/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
